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ActivationThis study systematically examined the viral long control region (LCR) activities and their responses to E2 for
human papillomavirus (HPV) types 11, 16, and 18 as well as bovine papillomavirus 1 (BPV1) in a number of
different cell types, including human cervical cancer cell lines, human oral keratinocytes, BJ ﬁbroblasts, as
well as CV1 cells. The study revealed cell- and virus-type speciﬁc differences among the individual LCRs and
their regulation by E2. In addition, the integration of the LCR into the host genome was identiﬁed as a critical
determinant for LCR activity and its response to E2. Collectively, these data indicate a more complex level of
transcriptional regulation of the LCR by cellular and viral factors than previously appreciated, including a
comparatively low LCR activity and poor E2 responsiveness for HPV16 in most human cells. This study
should provide a valuable framework for future transcriptional studies in the papillomavirus ﬁeld.
© 2009 Elsevier Inc. All rights reserved.Introduction
Papillomaviruses (PVs) contain circular double-stranded DNA
genomes of approximately 8000 base pairs. There are over 100 HPV
types with approximately 30 types associated with genital tract
lesions (de Villiers et al., 2004; Howley and Lowy, 2007). HPV types
that infect the genital epithelia are classiﬁed as either high-risk or
low-risk based upon their association with cancer. Although most
HPV infections get cleared by the host immune system, some
establish persistent infections. Persistent infection of high-risk HPVs
together with additional viral and host genetic or epigenetic changes
can lead to cervical cancer (Walboomers et al., 1999; zur Hausen,
2000), the second most common cancer in women worldwide, after
breast cancer (Parkin et al., 2005). With approximately 500,000 new
cases and about 275,000 deaths each year, cervical cancer accounts
for 15% of all new cancers in women in the developing world and for
about 3.5% in developed countries. The cumulative risk for women to
be diagnosed with cervical cancer up to age 65 is about 1.5% and 0.8%
in developing and developed countries, respectively (Parkin et al.,
2005).. Howley).
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tion is primarily driven by the two major viral oncogenes, E6 and E7,
whose best characterized cellular targets are the p53 and retino-
blastoma protein (pRB) tumor suppressors, respectively (Dyson
et al., 1989; Munger et al., 1989; Scheffner et al., 1990; Werness
et al., 1990). The early viral promoter within the LCR, a non-coding
region of approximately 700–1000 base pairs, controls E6 and E7
transcription. Along with cellular proteins, the papillomavirus E2
protein regulates the transcriptional activity from the LCR (Howley
and Lowy, 2007). In addition to its transcriptional roles, E2 directly
interacts with E1 and is involved in E1-dependent viral DNA
replication and genome maintenance (Abbate et al., 2004; Howley
and Lowy, 2007). Structurally, the E2 proteins are well conserved
among different PVs and range in size from approximately 350 to
400 amino acids (Giri and Yaniv, 1988; Harris and Botchan, 1999).
The E2 amino-terminal domain contains residues critical for binding
E1 and for transcriptional activation (Abbate et al., 2004; Giri and
Yaniv, 1988; McBride et al., 1991; Spalholz et al., 1985), whereas the
carboxy-terminal domain of E2 mediates homodimerization and
sequence-speciﬁc DNA binding (Chin et al., 1988; Haugen et al.,
1988). The amino- and carboxy-terminal domains of E2 are separated
via a less conserved hinge region (Giri and Yaniv, 1988; McBride et al.,
1991). Depending on the location of its cognate binding sites, E2 can
also act as either a transcriptional activator or repressor (Thierry and
Yaniv, 1987).
Transient transfection assays in a variety of cell types have shown
that full-length PV E2 can repress the early gene expression of genital
Table 1
LCR nucleotide positions represented in the pGL4.20-luciferase reporter vector of the
papillomaviruses used in this study.
Genome
size
Region cloned
into pGL4.20
L1 stop
codon
E6 start
codon
HPV11 7931 7072–104 7276 102–104
HPV16 7904 7000–100 7154 83–85
HPV18 7857 6943–107 7136 105–107
BPV1 7946 6958–93 7096 91–93
Genome sizes, nucleotide positions of the stop codon of the structural L1 gene, and the
start codon positions of the E6 oncogenes in HPV11, HPV16, HPV18, and BPV1 are
depicted. GenBank accession numbers for HPV11: M14119; for HPV16: NC_001526; for
HPV18: NC_001357; and for BPV1: NC001522.
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et al., 1994; Dong et al., 1994; Schweiger et al., 2007; Tan et al., 1992,
1994; Thierry and Howley, 1991; Thierry and Yaniv, 1987), although
some studies have reported activation at low E2 concentrations
(Bouvard et al., 1994; Schweiger et al., 2007; Steger andCorbach, 1997;
Thierry and Yaniv, 1987). The HPV18 E2 protein has been found to
repress its own LCR in a number of different cell lines, including C33A
cells, HeLa cells, and human keratinocytes (Bernard et al., 1989;
Dowhanick et al., 1995). The HPV16 E2 protein has been reported to
activate E2 binding site containing reporter plasmids in C33A cells
(Kovelman et al., 1996) but repress the HPV18 LCR in C33A and HeLa
cells (Dowhanick et al., 1995). Low-risk HPV11 E2 has been shown to
repress its autologous LCR in C33A cells (Chin et al., 1989; Dong et al.,
1994; Schweiger et al., 2007;Wu et al., 2006). In contrast to repression
of the LCR for the genital tract HPV types, E2 proteins generally activate
transcription of the BPV1 LCR as well as reporter plasmids containing
multiple tandem E2 binding sites (Kovelman et al., 1996; Spalholz et
al., 1985; Ushikai et al., 1994). Whereas the BPV1 LCR contains 12 E2
binding sites (Li et al., 1989), the genital HPV type LCRs contain only
four in a conserved spatial arrangement. It is well established that
BPV1 E2 robustly activates transcription regulated by its own LCR
(Goodwin et al., 1998; Haugen et al., 1987, 1988; Hawley-Nelson et al.,
1988; Spalholz et al., 1985, 1987). In contrast, BPV E2 as well as some
HPV E2s repress transcription from HPV LCRs and, upon ectopic
expression, cause senescence in HPV-positive cervical cancer cell lines
through repression of E6 and E7 gene expression (Dowhanick et al.,
1995; Goodwin and DiMaio, 2000; Goodwin et al., 1998; Hwang et al.,
1993, 1996; Wells et al., 2000, 2003). Independent studies using
different PV types, experimental systems, e.g., in vitro versus cell-
based assays, or variable cell lines and vector systems, have made it
difﬁcult to arrive at a predictive comprehensive understanding of viral
LCR activity with its possible implications for the oncogenic potential
of different HPV types.
Therefore, this study was designed to consolidate and extend the
existing information regarding PV transcriptional functions by
performing side-by-side comparisons for the low-risk HPV11, the
high-risk HPV16 and HPV18, as well as the frequently studied BPV1.
The transcriptional activity of the E6 promoter under the inﬂuence of
all enhancer and silencer elements of the LCR (from hereon referred to
as ‘LCR activity’) was investigated for these four different papilloma-
viruses. Furthermore, the effect of their respective E2 proteins on LCR
activity in various combinations was assessed. The analyses were
performed in six different cell types, including four human cell types
of epithelial origin: the cervical carcinoma cell lines C33A (HPV
negative), HeLa (HPV18 positive), SiHa (HPV16 positive), and human
telomerase (hTERT)-immortalized normal human oral keratinocytes
(NOK hT). In addition, hTERT-immortalized human ﬁbroblasts (BJ hT)
and African Green Monkey kidney epithelial cells (CV1) were
examined.
The results from this study extend our current understanding
of PV transcriptional control. We determined that PV LCRs have
different levels of activity that vary in a cell-type dependent
manner. When examining the regulatory properties of E2 proteins,
we found levels of complexity not previously appreciated that are
both virus- and cell-type speciﬁc. Furthermore, using C33A cells
with integrated HPV18 LCR, we observed that the site of integration,
and not the viral DNA copy number, was a determinant for the LCR
activity as well as the ability of E2 to repress transcription from the
LCR. Overall, this study reveals an unanticipated complexity in the
ﬁeld of PV–host interactions in the functions governing E2
transcriptional regulation of the viral LCR attributable to differences
in both cellular and viral factors. Together, these ﬁndings should
provide a framework for the interpretation of PV transcriptional
data and for future experimental design, as well as for the mole-
cular understanding of factors that contribute to cervical cancer
progression.Results
A more comprehensive understanding of the commonalities and
differences in PV LCR activity and regulation by E2 is important for
the broader understanding of PV-induced malignancies and progres-
sion to cervical cancer because the two major oncogenes E6 and E7
are under the transcriptional control of the LCR. Although a large
number of studies have added to our understanding of PV trans-
criptional functions, the interpretation and comparability of the
overall data are hampered due to the use of different E2 proteins and
variations in experimental systems. Thus we set out to systematically
evaluate the activity of the LCR driving expression of a luciferase
reporter and its ability to be regulated by E2 proteins in a series of
different cell types.
The LCR activities of HPV11, HPV16, HPV18, and BPV1 exhibit cell-type
speciﬁc differences
LCR activities were compared through use of various LCR-
luciferase reporter constructs representing the HPV11, HPV16,
HPV18, and BPV1 LCRs. For consistency in reporter construction, all
LCRs introduced into the promoterless pGL4.20 vector spanned
approximately 1000 nt upstream of the E6 start site. Incorporation
of the E6 start codon in frame with the luciferase open reading frame
ensured the most physiologically relevant comparison of these
luciferase transcripts to PV early transcripts derived from and
regulated by the viral LCR. Speciﬁc characteristics of these reporter
constructs, named pGL4-LCRHPV11, pGL4-LCRHPV16, pGL4-
LCRHPV18, and pGL4-LCRBPV1, are shown in Table 1 (Schweiger
et al., 2007). Transient reporter assays in C33A, HeLa, SiHa, NOK hT,
BJ hT, and CV1 cells were performed. Several wells of cells were
transfected with an EGFP-encoding plasmid in parallel to each assay,
to determine transfection efﬁciencies of the various cell lines.
Transfection efﬁciencies were approximately 10% for SiHa cells and
BJ ﬁbroblasts, 25% for NOK cells, 40% for C33A and CV1 cells, and 50%
for HeLa cells (data not shown). The range in transfection efﬁciencies
meant that quantitative comparisons of LCR activities could only be
made within the same cell type.
Next, all six cell lines were transfected with the four LCR-
luciferase reporter constructs to characterize the LCR activities in
the absence of E2. Luciferase activity measurements were normal-
ized to the levels detected with empty pGL4.20 vector (Fig. 1, left
columns) which exhibited detectable luciferase activity above back-
ground levels. To control for potential differences in transfection
efﬁciency all experiments were conducted at least three indepen-
dent times in duplicate. Furthermore, an SV40-βGAL plasmid was
always cotransfected and the β-gal activity determined alongside
the luciferase activity. Data normalized to β-gal are shown in
Supplementary Fig. S2 and are similar to the data without β-gal
normalization in Fig. 1.
The HPV11 LCR exhibited the highest LCR activity in each of
the six cell lines, ranging from 27-fold in BJ ﬁbroblasts to 400-fold
Fig. 1. Cell-type speciﬁc differences of HPV11, HPV16, HPV18, and BPV1 LCR activities.
Luciferase reporter assays to investigate the intrinsic promoter activities of HPV11,
HPV16, HPV18, and BPV1 LCRs were performed in C33A (A), HeLa (B), and SiHa (C), in
NOK (D) and BJ ﬁbroblasts (E), and CV1 cells (F). Cells were transfected with 25 ng
empty reporter plasmid pGL4.20 or papillomavirus LCR reporter plasmids pGL4-
LCRHPV11, pGL4-LCRHPV16, pGL4-LCRHPV18, or pGL4-LCRBPV1 together with 350 ng
of empty vector pCMV. Forty-eight hours later, cells were lysed and lysates were
analyzed for luciferase activities. Luciferase activities are depicted relative to pGL4.20.
Data represent the mean of three independent experiments each performed in
duplicate±SD. RLU: relative light units. Relative activities are given as numbers above
each column.
Fig. 2. HPV11 and HPV16 LCRs exhibit similar activities in stable reporter cell pools
compared to transient assays. Pools of stable C33A (A, n= 4) and CV1 (B, n=5) cells
were generated by transfecting cells with linearized pGL4.20, pGL4-LCRHPV11, or
pGL4-LCRHPV16 followed by puromycin selection. Cells were lysed and analyzed for
luciferase activity. Data represent mean relative luciferase activities±SD compared to
pGL4.20. Relative activities are given as numbers above each column.
Fig. 3. HPV11 and HPV18 E2 proteins repress their autologous LCRs in C33A but not in
SiHa cells. HPV11 E2 and HPV18 E2 proteins were titrated on their autologous LCRs.
C33A or SiHa cells were cotransfected with 25 ng of LCR-luciferase reporter plasmid
together with increasing amounts of HPV11 E2 (pCMV-E211) or HPV18 E2 (pCMV-E218)
plasmids. Total amounts of DNA were kept constant at 850 ng by using pCMV empty
vector. E2 (ng) indicates the amount of E2 expression plasmid per well. Luciferase
activity in the absence of E2 was set at one. Activities were normalized for E2's effects
on luciferase activity in pGL4.20 transfected cells. Data represent mean relative
luciferase activities of two independent experiments each in duplicate + SD. Note the
y-axis is displayed as a logarithmic scale.
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column). In contrast, the LCR of HPV16, the most prevalent and
pathogenic genital HPV type, exhibited only weak activity in C33A,
SiHa, and BJ cells, in the range of 2- to 3-fold over the empty vector,
but was more active in other human cells (Figs. 1A–E, middle, dashed
column). Compared to the HPV11 LCR, the HPV16 LCR exhibited
low activity in all human cells. In contrast, the HPV16 LCR ex-
hibited high activity in CV1 cells, with a relative activity 38-fold over
empty vector, a level comparable to that of the HPV11 LCR (Fig. 1F).
The HPV16 LCR reporter construct used in this study had been cloned
slightly differently than the others, containing 15 additional nucleo-
tides of E6 coding sequence (see Table 1, nt 86–100). Because of the
possibility that this difference could have been responsible for the low
activity of the HPV16 LCR, we recloned the HPV16 LCR in a manner
identical to the other reporter constructs (nt 7000–85). These two
HPV16 LCR reporter constructs, however, showed comparable LCR
activities in all six cell lines (Supplementary Fig. S1). The HPV18 LCR
was active in all human cells, albeit consistently weaker than theHPV11 LCR, but more active than HPV16 or BPV1 LCRs. In contrast,
in CV1 cells the HPV18 LCR activity was weakest (Figs. 1A–F, fourth,
grey column). The BPV1 LCR showed high activity in C33A, HeLa, SiHa,
and CV1 cells, moderate activity comparable to HPV18 LCR in BJ
ﬁbroblasts, but was the weakest of all LCRs in NOKs (Figs. 1A–F, right
column).
In summary, the LCR activity in the absence of E2 varied depending
on the PV type from which the LCR originated. Within any given cell
line examined, the relative activity trends of the individual LCRs were
HPV11NHPV18NBPV1NHPV16, with two exceptions: (i) in NOK cells
BPV1 LCR exhibited the weakest activity, and (ii) in CV1 cells, HPV16
and HPV18 swapped their ranks with high activity of HPV16 LCR and
164 M. Ottinger et al. / Virology 395 (2009) 161–171
165M. Ottinger et al. / Virology 395 (2009) 161–171low activity of HPV18 LCR. These data suggest not surprisingly that
cellular factors play a critical role in determining papillomavirus LCR
activity. Although LCR activities varied between cell types, the relative
activity trends were generally consistent across the cell lines used in
this study.
Integration of the LCR into host DNA does not alter its activity in pools of
stable cells
The LCR activity measured in the transient experiments (Fig. 1)
mimics the transcriptional activity expected from PV genomes in
their extrachromosomal episomal state during productive or
persistent infection. However, PV genomes are often found integrat-
ed into cellular DNA in cervical cancer samples. Thus, it was
important to examine whether the relative LCR activities were
affected by the integration process. To address this, C33A and CV1
cells were transfected with linearized pGL4.20, pGL4-LCRHPV11, or
pGL4-LCRHPV16 reporter constructs. Pools of stable cells with
randomly integrated DNAs were generated by puromycin selection
and luciferase activities were determined. Despite the likely
differences in the LCR activity of any one integration event within
the stable pools of C33A (Fig. 2A) and CV1 (Fig. 2B) cells harboring
the HPV11 or HPV16 LCR-controlled luciferase reporter, the net LCR
activities within these pools of stable cells were consistent with what
was observed in the transient episomal assays performed in Fig. 1.
Therefore, within a given cellular context, heterogeneous popula-
tions of cells with integrated LCRs exhibit similar LCR activities as in
transient assays.
HPV11 and HPV18 E2 proteins repress their autologous LCRs in C33A
cells but not in SiHa cells
Previous studies have shown variable viral LCR responses to
different E2 proteins (Bernard et al., 1989; Bouvard et al., 1994; Chin
et al., 1988, 1989; Demeret et al., 1994; Schweiger et al., 2007; Steger
and Corbach, 1997; Tan et al., 1992, 1994; Thierry and Howley, 1991;
Thierry and Yaniv, 1987). Thus, the transient luciferase reporter assay
studies were extended to include an analysis of E2-type speciﬁc
transcriptional modulation of a given viral LCR. In these experiments,
the dose-dependent effects of HPV18 E2 on the HPV18 LCR and of
HPV11 E2 on the HPV11 LCR were analyzed and compared with the
data in one of our previous studies in which we titrated HPV16 E2
(Schweiger et al., 2007). Cells were transiently transfected with an E2
expression plasmid (at concentrations ranging from 1 to 512 ng)
along with a constant amount (25 ng) of LCR-luciferase reporter
plasmid. In C33A cells, the LCRs of HPV11 and HPV18 were either
not affected or mildly activated at lower E2 concentrations (Fig. 3A,
1–32 ng of E2 DNA). When the E2:LCR reporter plasmid ratio was
higher than 2:1 (Fig. 3A, 64 –512 ng), the LCRs were repressed up to
about 3-fold in a dose-dependent manner. This was consistent with
previously published work (Schweiger et al., 2007; Steger and
Corbach, 1997). In contrast to the activity observed in C33A cells,
HPV11 E2 and HPV18 E2 only moderately activated their autologous
LCR reporters in SiHa cells to levels no higher than 3-fold at all E2
concentrations examined (Fig. 3B). This may suggest that some cells
support E2-mediated repression of the LCR (e.g., C33A) whereas
others do not (e.g., SiHa). It is possible that E2 expression or stabilityFig. 4. Regulation of HPV11, HPV16, HPV18, and BPV1 LCRs by E2 proteins shows virus-type
transiently transfected with 25 ng pGL4.20 or one of the four papillomavirus LCR reporter co
E2 (pCMV-E211), HPV16 E2 (pCMV-E216), HPV18 E2 (pCMV-E218), or BPV1 E2 (pcDVL-E2BPV)
luciferase activity in pGL4.20 transfected cells. Relative luciferase activities compared to mo
panel (columns 17–20) because the BPV1 E2 expression plasmid was in a different vector ba
luciferase activity between the two vector backbones in these assays (data not shown). Da
performed in duplicate + SD. Relative activities are given as numbers above or below eachmay vary between these cell lines and may possibly account for some
of the observed differences in LCR response observed. This explana-
tion would suggest that cellular factors might differentially modulate
the LCR activity, albeit indirectly through E2 protein levels. We
conclude from these experiments that speciﬁc cellular factors must be
determinants for the E2 function to act as transcriptional repressors
on the LCR.
Virus and cell-type speciﬁc differences in the ability of the E2 protein to
regulate papillomavirus LCR activity
Given that the LCR activities varied based on the cellular context,
HPV11, HPV16, HPV18, and BPV1 E2 proteins were assayed for their
effects on their LCR elements in various combinations in the six
different cell lines. Similar to our studies of LCR activity in the absence
of E2 (Fig. 1), we utilized transient transfections, because the circular
DNA status of the LCR reporter is possibly reﬂective of the state of
PV episomes in infected cells. Based upon our titration experiments
(Fig. 3) and previously published work (Schweiger et al., 2007), an
experimental design with constant and relatively high quantities of
E2 expression plasmid was chosen (E2 plasmid to reporter plasmid
ratio of 14:1) to control for variable expression of the different E2
proteins and ensure E2 levels were high enough to confer a repressor
activity.
The LCR activities in the presence of E2 were calculated relative
to those in the absence of E2 and the latter were set to a value of one
(Fig. 4). Because the expression of some E2 proteins in certain cell
types caused up to 2-fold increase in β-gal activity, the luciferase data
presented in Fig. 4 is not normalized to β-gal. Compared to the data in
Fig. 4, the results obtained for C33A, HeLa, and NOK cells with β-gal
correction (Supplementary Fig. S3) show only minor quantitative
differences. In C33A cells, all HPV E2 proteins repressed HPV11 and
HPV18 LCR activities to about one third of the initial activity. The
HPV16 LCR was not active in these cells and was therefore not
repressed by E2 (compare Fig. 1A with Fig. 4A, columns 5–8). In HeLa
cells, all E2 proteins repressed all of the HPV LCRs except for the
HPV16 E2 and HPV11 LCR combination where no signiﬁcant
repression was observed (Fig. 4B). In SiHa cells, none of the LCRs
were repressed (Fig. 4C). In fact, the already high activity of HPV11
LCR (Fig. 1C) was enhanced further by the addition of HPV E2 (Fig.
4C). Similarly, the BPV1 LCR was also activated by all E2 proteins in
SiHa cells (Fig. 4C). In oral keratinocytes, repression of LCR activity by
E2 was restricted to certain conditions (Fig. 4D). HPV11 E2 and HPV18
E2 repressed the HPV18 LCR and HPV11 E2 showed a tendency to
repress the HPV16 LCR (Fig. 4D). Interestingly, HPV16 E2 did not
signiﬁcantly repress any LCRs in oral keratinocytes; it activated the
HPV11 LCR and HPV18 LCR (Fig. 4D). Similar to what was observed in
SiHa cells, no LCR repression was observed by any E2 in human BJ
ﬁbroblasts (Fig. 4E). In CV1 cells, the only non-human cell line used in
this study, the HPV16 LCR exhibited high activity (Fig. 1) and was
repressed by all E2 proteins (Fig. 4F). The HPV18 LCR, which displayed
low activity, was activated by E2 (compare Fig. 1F with Fig. 4F,
columns 14–16).
As in SiHa cells, the BPV1 LCRwas consistently activated by HPV E2
proteins as well as by BPV1 E2 in NOK, BJ, and CV1 cells (Figs. 4C–F,
columns 14–16 and 20). As expected, BPV1 E2 activated the BPV1 LCR
in all cells examined and therefore served as a reference E2-and cell-type speciﬁc differences. C33A, HeLa, SiHa, NOK hT, BJ hT, and CV1 cells were
nstructs plus 350 ng of pCMV empty vector (mock), or expression constructs for HPV11
. Cells were harvested as described in Fig. 1. Activities were normalized for E2's effect on
ck (pCMV) transfected cells are displayed. The effect of BPV1 E2 is shown in a separate
ckbone (pcDVL rather than pCMV). We did not observe any vector-based differences in
ta represent mean relative luciferase activities of three independent experiments each
column.
Fig. 5. Clone to clone variability in HPV18 LCR activity and E2 responsiveness do not
correlate with HPV18 LCR copy numbers. C33A/E2TA/HPV18LCR single-cell clones
were lysed and luciferase activities in the presence of BPV1 E2 were determined and
normalized to the total amount of protein in the cell lysates (A–E, mock, black
columns). Cells were transfected with one of two BPV1 E2-speciﬁc siRNA duplexes
(E2#1 and E2#3) or a non-targeting control (scr) siRNA. The effectiveness of BPV1 E2
knock-down was determined by immunoblotting for HA. Actin immunoblots served
as the control for equal loading. (F) Copy numbers of the HPV18 LCR-luciferase re-
porter were determined by HPV18 LCR speciﬁc quantitative PCR in triplicate and are
depicted±SD.
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these data show that E2 proteins exhibit differences in their ability to
repress transcription and that this varies by papillomavirus type and
the cell type.
The integration site is a critical determinant for LCR activity
In many cervical cancers, the high-risk HPV genome can be found
integrated into the host genome. Interestingly, there appear to be
virus-type speciﬁc differences in the frequency of integration.
Transcripts from integrated viral copies are detected in almost all
cases of HPV18-induced malignancies, whereas the integration
frequency in HPV16-induced malignancies is approximately 60%
(Vinokurova et al., 2008). To investigate whether the site of
integration inﬂuences LCR activity, the C33A/E2TA cell line which
stably expresses the BPV1 E2 protein (You et al., 2004) was further
engineered by the stable introduction of linearized pGL4-HPV18 LCR-
luciferase reporter DNA. Cells were selected with puromycin and
clonal lines from single cells were established. The luciferase activity
of representative clonal cell lines is shown in Fig. 5. Some cell lines had
undetectable LCR activity (Fig. 5B, black column), whereas others
exhibited moderate (Figs. 5A and D, black columns) or high LCR
activity (Figs. 5C and E, black columns). To test whether differences in
LCR activity were a function of the number of integrated LCR-
luciferase DNA copies, quantitative PCR was performed to determine
LCR copy numbers in individual stable cell lines. Copy numbers were
found to range from 2 to 10 copies per cell (Fig. 5F). No obvious
correlation between LCR copy numbers and LCR-driven luciferase
activity was observed in these cells (Fig. 5, compare F with A to E, left
two columns), which supports the idea that the integration location is
a critical determinant of LCR activity. This may be due to differences in
chromatin state of the integrated DNA and/or due to different cis-
regulatory elements in the host genome regulating the expression
from the LCR in these stable cell lines.
The LCR integration site inﬂuences the ability of E2 to regulate
transcriptional activity from the LCR
Because BPV1 E2 is present in C33A/E2TA/HPV18LCR cells, it was
important to next test whether the observed levels of LCR activity
were regulated by E2. BPV1 E2 expression was knocked-down with
two different siRNA duplexes targeting different regions of the E2
transcript. For both siRNAs, the knock-down efﬁciency was robust as
indicated by anti-HA immunoblots for HA-tagged E2TA (Figs. 5A–E,
immunoblots). These experiments revealed that some single-cell
clones had integrated LCRs that remained responsive to regulation
by the endogenously expressed E2 protein, which was apparent by
the elevated luciferase activity in E2 siRNA knock-down samples.
Thus, BPV1 E2 repressed the HPV18 LCRs in C33A cells (Figs. 5C–E).
However, other single-cell clones showed no or very weak respon-
siveness to E2 knock-down (Figs. 5A and B), presumably because the
integration event occurred in a silenced region or resulted in the loss
(or loss of accessibility) of functional elements important for E2-
mediated regulation. Collectively, these data provide evidence that
the site of integration, and not the number of integrated copies, is a
major determinant of LCR activity as well as for the ability of E2 to
repress transcription from the LCR in the context of a speciﬁc clonal
cell line.
Discussion
The papillomavirus E2 protein plays important roles in viral DNA
replication and transcription. Through its interaction with the viral
E1 helicase, E2 helps to recruit E1 to the origin of viral DNA replica-
tion in the LCR (Frattini and Laimins, 1994; Hughes and Romanos,
1993). As a transcription factor, E2 can function either as an activator
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Corbach, 1997; Thierry and Howley, 1991). When expressed at high
levels in cervical cancer cells harboring integrated HPV genomes, E2
represses the HPV16 P97 or HPV18 P105 promoters, thereby reducing
E6 and E7 transcription and leading to cellular senescence or
apoptosis (Desaintes et al., 1997; Dowhanick et al., 1995; Goodwin
and DiMaio, 2000; Goodwin et al., 1998; Nishimura et al., 2000).
Numerous studies have been performed to investigate papillomavirus
transcriptional functions. However, it is often difﬁcult to compare
results between studies due to the variation in experimental systems
and procedures used, in particular the different cell lines, different
vector systems, and combinations of different viral LCRs and diffe-
rent E2 proteins. Therefore, this study was designed to characterize
the LCR activities for HPV11, HPV16, HPV18, and BPV1 in several
different cell lines using comparable conditions and identical vector
backbones.
Differences in LCR activities in the absence of E2
The four LCR-luciferase reporter constructs uniformly encom-
passed a 1000 nt HPV genome sequence of the LCR up to, and
including, the E6 start codon with the intent that the luciferase
protein would initiate from the E6 methionine AUG codon. Our data
show that the HPV11 and HPV18 LCRs were transcriptionally active
in all human cells, whereas the HPV16 LCR activity was compara-
tively weak in human cells (Fig. 1). In contrast, in CV1 cells, the only
non-human cell line in this study, the HPV16 LCR was signiﬁcantly
more active whereas HPV18 LCR was weaker (Fig. 1F). The LCR
activities could be ranked in the following order: HPV11NHPV18N
BPV1NHPV16 with the exceptions of HPV18 and HPV16 swapping
ranks in CV1 cells and BPV1 exhibiting the weakest activity in
human oral keratinocytes. Interestingly, the LCR of HPV16, the HPV
type found in more than 50% of cervical cancers, had the lowest LCR
activity in all human cells. It should be noted that nucleotide
differences in the LCRs of different variants of the same HPV types
might also affect the level of activity from individual isolates
(Bhattacharjee and Sengupta, 2006a,b; Lace et al., 2009). Such
potential variability within virus types was not examined in this
study. To compare the degree of sequence conservation within the
LCRs, we generated ClustalW alignments of the HPV11, HPV16,
HPV18, and BPV1 LCRs. This analysis revealed that the HPV11 and
HPV18 LCRs are 52% identical, whereas HPV11 and HPV16 LCRs are
20.7% identical, and the level of identity between HPV16 and HPV18
LCRs is 19%. Therefore, the LCRs of HPV11 and HPV18 appear to be
most closely related to one another. This contrasts with the
phylogenetic classiﬁcation schemes that, based on the L1 open
reading frame, show similar distances between each HPV pair with
60–70% sequence identity (de Villiers et al., 2004). Based on the
degree of similarity in the L1 gene, HPV11, HPV16, and HPV18 all fall
into the α-genus of the family Papillomaviridae (de Villiers et al.,
2004). In contrast, BPV1, a member of the δ-genus, does not share
sequence identity in its LCR by the ClustalW alignment analysis with
any of the HPV LCRs included in this study (data not shown). These
similarities and differences are exempliﬁed by the location and
frequency of E2 binding sites (E2BS) in the LCR. The BPV1 LCR
contains 12 E2BS (Li et al., 1989) whereas HPV LCRs contain four in
a conserved spatial arrangement, with two E2BS close to the TATA
box, one E2BS approximately 100 nt upstream, and another around
500 nt upstream of the E6 ATG.
Given that the frequency and arrangement of the E2BS in different
HPV LCRs are conserved, other characteristics of the LCRs must be
responsible for the differences observed in LCR activity. The diversity
in LCR architecture, speciﬁcally frequency and location of transcrip-
tion factor binding sites for cellular transcription factors together with
differences in speciﬁc cellular environments, is likely to contribute to
the variation in LCR activities in the absence of E2.Commonalities and differences in the ability of E2 to transcriptionally
regulate various LCRs
Transient transfection assays in a variety of cell types have shown
that the full-length PV E2 protein can repress the early gene
expression of genital HPV types (Bernard et al., 1989; Chin et al.,
1988, 1989; Demeret et al., 1994; Dong et al., 1994; Schweiger et al.,
2007; Tan et al., 1992, 1994; Thierry and Howley, 1991; Thierry and
Yaniv, 1987), although some studies have reported transcriptional
activation at low E2 concentrations (Bouvard et al., 1994; Schweiger
et al., 2007; Steger and Corbach, 1997; Thierry and Yaniv, 1987). In
contrast to the repression of the LCR for the genital tract HPV types, E2
proteins generally activate transcription of the BPV1 LCR or reporter
plasmids containing multiple E2 binding sites (Kovelman et al., 1996;
Spalholz et al., 1985; Ushikai et al., 1994). The current model is that
HPV LCRs are repressed by high levels of E2, whereas the BPV1 LCR is
activated by E2. Since the abovementioned studies were performed in
different experimental systems, we asked if similar results were
obtained when we attempted to control for such experimental
variation. To do so, we utilized luciferase reporter assays with four
LCR reporters in combinationwith different E2 proteins in six cell lines
(Figs. 3 and 4). Because we worked with untagged E2 expres-
sion constructs in order to minimize potential artefacts induced by
the tags, E2 protein levels were not directly controlled for in the
transient assays. However, based on the E2 titration experi-
ments depicted in Fig. 2 and those previously performed (Schweiger
et al., 2007), we chose to use high levels of E2 expression plasmid
in our transient assays, and expressed all HPV E2 proteins from the
same vector. Furthermore, the results obtained in this study are in
general agreementwith observations previously published in theﬁeld.
Each of the cell lines examined were shown to be capable of
supporting the transcriptional activation function of the BPV1 E2
protein activating the BPV1 LCR (e.g., Figs. 4A–F, column 20).
Therefore, BPV1 served as a reference E2-responsive construct for
this set of experiments. This study deﬁnitively shows that some cell
lines were permissive for E2-mediated transcriptional repression,
presumably through the expression of critical intrinsic host factors
supportive of E2-mediated transcriptional repression. In contrast, two
of the cell lines, SiHa cells and BJ ﬁbroblasts, did not support
transcriptional repression by E2 (Figs. 3B and 4C and E). This was
most likely not due to possible differences in E2 expression levels,
because the BPV1 LCR was consistently activated by all E2 proteins in
both SiHa and BJ cells similarly to NOK and CV1 cells (Fig. 4, compare C
and E with D and F, lanes 14–16 and 20), and at these E2 levels robust
repression of the HPV16 LCR and HPV18 LCR by E2 did occur (Fig. 4F,
lanes 6–8, and D, lanes 10 and 12).
We found that the LCR activity of HPV11 and HPV16 LCRs did not
change with integration when comparing transient transfection
results with those from pooled stably transfected cells (compare
Figs. 1A and F with Fig. 2). However, E2 siRNA knock-down
experiments in clonal cell lines with integrated HPV18 LCR-luciferase
reporters and stable BPV1 E2 revealed that the ability of E2 to repress
the HPV18 LCR was cell line and therefore integration event
dependent (Fig. 5). This clearly demonstrates that within a clonal
population of cells, the location of the integration site can have a
dramatic effect on the viral LCR activity. This ﬁnding has profound
implications for cervical cancer. HPV DNA integration in cervical
epithelial cells can occur over years or even decades with persistent
infection, sometimes with numerous viral copies per cell (Baker et al.,
1987; Yee et al., 1985). Our data suggest that the number of
integrated LCR elements was less important for LCR activity or E2
responsiveness (Fig. 5). However, the location or type of integration
event may be an important determinant for malignant progression
presumably because events that result in a loss of the ability of E2 to
repress the LCR and therefore higher expression of the E6 and E7
oncogenes would provide the cell with a selective carcinogenic
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loss of E2 have such a growth advantage (Howley and Lowy, 2007).
Interestingly, our results suggest that integration of the LCR could be
an equally important determinant for the oncogenic potential of a cell
even with E2 still being present.
In line with our observations, Bechtold et al. have recently shown
for HPV16 that E2 can repress transcription of the viral LCR only when
the HPV genome is integrated into the host genome and not when it is
present in an episomal, non-integrated form. This difference was
attributed to the chromatin structure around the E6/E7 promoter at
the site of integration rather than the integration event itself
(Bechtold et al., 2003). It has been suggested that nucleosomes may
play a regulatory role in the activities of the HPV LCRs (Stunkel and
Bernard, 1999). The chromatin state of the LCR may be critical for the
accessibility and binding of certain transcription factors to the LCR and
thereby determine its responsiveness to E2 and to cellular transcrip-
tion factors. The sites of viral integration in cellular DNA are
distributed throughout the host genome (Wentzensen et al., 2004).
No cellular sequence motifs have been identiﬁed as being preferential
for integration. However, common fragile sites, unstable genomic
regions that frequently are transcriptionally active, are overrepre-
sented among HPV integration sites (Thorland et al., 2000, 2003). It is
unclear whether this is because integration is facilitated in accessible
active regions, or because there is a selective advantage for the virus to
be robustly transcribed (Pett and Coleman, 2007).
Besides the integration site as a determinant of LCR activity,
speciﬁc transcription factors have been implicated in the regulation of
LCR promoters. It has been demonstrated that E2 can displace Sp1
from the binding site positioned upstream of the two promoter
proximal E2BS for HPV11 and HPV16 (Dong et al., 1994; Tan et al.,
1994) and this may contribute to its transcriptional repression
function. However, the carboxy-terminal DNA-binding domain of E2
by itself and certain amino-terminal mutants of E2, which retain the
capability to bind to E2 binding sites, are unable to repress HPV LCR
activity (Baxter et al., 2005; Dowhanick et al., 1995; Francis et al.,
2000; Goodwin et al., 1998; Nishimura et al., 2000). This indicates that
the E2 transcriptional repression function is not exclusively mediated
by the displacement of cellular factors from the E6/E7 promoter, but
likely through the active recruitment of repressor molecules by the E2
amino-terminal domain. Furthermore, mutational analyses of E2
revealed that the same amino acid mutations in the amino-terminal
domain of E2 that impair transcriptional activation also inhibit
transcriptional repression (Baxter et al., 2005; Goodwin et al., 1998;
Nishimura et al., 2000). It has been shown recently by our laboratory
and by others that the E2 transcriptional activation function of a
number of papillomaviruses is mediated by the cellular bromodomain
containing protein Brd4 (Ilves et al., 2006; McPhillips et al., 2006;
Schweiger et al., 2006; Senechal et al., 2007). E2 directly interacts with
Brd4 (Abbate et al., 2006; You et al., 2005). In addition, it has been
suggested that Brd4 also plays a role in E2 mediated transcriptional
silencing (Wu et al., 2006). However, there is also evidence for Brd4
independent mechanisms of repression (Schweiger et al., 2007).
Interestingly, the gammaherpesviruses Kaposi's sarcoma herpesvirus
(KSHV), murine gammaherpesvirus 68 (MHV-68), and Epstein–Barr
virus (EBV) interact with Brd4 via their orf73/LANA and EBNA-1
proteins, proteins with functional similarities to E2, and these
interactions play a role in the transcriptional functions of orf73/
LANA and EBNA-1 (Lin et al., 2008; Ottinger et al., 2006, 2009; You
et al., 2006).
Most strikingly, the HPV16 LCR displayed the lowest LCR activity
in the absence of E2 in each of the human cell lines examined (Fig. 1).
Furthermore, it was only repressed by E2 in HeLa and CV1 cells
(Fig. 4), two cell lines in which the HPV16 LCR was relatively active
(Fig. 1). This observation of poor E2 responsiveness for HPV16 may
provide a possible mechanistic link to the phenomenon that in
HPV16-induced cervical cancers, the viral DNA is more frequentlyfound in an episomal state compared to HPV18 positive cervical
cancers (Vinokurova et al., 2008). Because the HPV18 E2 robustly
represses its autologous LCR (Fig. 4), loss of E2 would generally
confer a growth advantage due to deregulated HPV18 E6/E7 expres-
sion, whereas in HPV16 infected cells, loss of E2 might provide a
much weaker growth advantage. Therefore, the ﬁndings presented in
this work provide molecular support for the epidemiologic evidence
that there are HPV type speciﬁc differences with regards to the
frequency of viral integration observed in disease progression (Pett
and Coleman, 2007).
Clearly, the oncogenic potential of a given HPV type is complex
and can be attributed to several factors. Intrinsic differences in the
activities of the E6 and E7 proteins have been documented (Barbosa
et al., 1991). This present study illustrates that there are also clear
differences in the LCR activity responsible for driving E6/E7
expression. As demonstrated in Fig. 5, the number of integrated HPV
DNA copies does not seem to be important for LCR activity. Supporting
this notion is the fact that cervical cancer cell lines differ dramatically
in the viral copy numbers with approximately one to two HPV16
copies per cell in SiHa cells to around 600 HPV16 copies per cell in
Caski cells with all but one copy epigenetically silenced in the Caski
cells (Baker et al., 1987; Yee et al., 1985).
In addition, this study shows that there is a variable ability of
individual E2 proteins to regulate the same LCR. Collectively, these
parameters all contribute to the potential of an HPV type to promote a
growth advantage for a cell harboring the virus. However, our results
establish that there is a strong cell-dependent variable on the ﬁnal LCR
activity. Besides being important for cross-study comparison, this
ﬁnding is important in the clinical setting because a comprehensive
understanding of the cellular contributions to the viral LCR activity
may be advantageous for a better design of antivirals or other thera-
peutic strategies which aim at reducing E6 and E7 levels.
Some of the potential cellular determinants could include cellular
genetic or epigenetic changes affecting any of these regulatory levels,
or factors or pathways downstream of E6 and E7. Such changes could
confer a selective advantage for an individual cell and ultimately
contribute to carcinogenic progression. For example, the CpG
methylation of E2 binding sites in the LCR has been associated with
cervical cancer in the presence of intact E2 in HPV16 positive cancers
(Bhattacharjee and Sengupta, 2006a). Our study highlights the
complexity of papillomavirus–host interactions on the LCR. E2 levels,
chromatin state (Stunkel and Bernard, 1999), and cis-regulatory
elements in the host genome are likely to be important determinants
of the activity of integrated LCRs. Furthermore, a balance of speciﬁc
cellular factors (e.g., transcription factors and repressor complexes) in
an HPV infected cell would be required for the relative activity of a
speciﬁc LCR that would result in E6/E7 levels favorable for cellular
growth. Genome wide studies are on their way in our laboratory to
identify novel cellular factors involved in E2 mediated transcriptional
repression. Ultimately, a comprehensive understanding of the
regulatory mechanisms governing PV early gene transcription of the
E6/E7 oncogenes will be valuable to the PV ﬁeld as well as for the
molecular understanding of cervical cancer pathogenesis.
Material and methods
Cell culture methods
The cervical carcinoma cell lines C33A (HPV negative), C33A/
E2TA (C33A cell line stably expressing full-length BPV1 E2) (You et
al., 2004), HeLa (HPV18 positive), and SiHa (HPV16 positive) as well
as African Green Monkey kidney epithelial cells CV1 were cultured at
subconﬂuence in high glucose Dulbecco' modiﬁed Eagle's medium
(hgDMEM, Gibco) supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 50 IU/ml penicillin, and 50 μg/ml streptomycin
(P/S). HTERT-immortalized human normal oral keratinocytes
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cultured at subconﬂuence in keratinocyte medium (EpiLife Medium
supplemented with human keratinocyte growth supplements
[both Cascade Biologics] according to themanufacturer's instructions)
plus P/S. Human BJ ﬁbroblast cells immortalized with hTERT (BJ hT), a
gift fromWilliam Hahn, were cultured at subconﬂuence in BJ medium
(68% knockout DMEM, 17% Medium 199 [both Gibco], 15% heat-
inactivated FBS) supplemented with P/S and 100 μg/ml glutamine.
DNA constructs
The expression vectors for HPV11 E2 (pCMV-E211, p2090), HPV16
E2 (pCMV-E216, p3662), HPV18 E2 (pCMV-E218, p2092), BPV1 E2
(pcDVL-E2BPV, p2450), and pSVβ-GAL have been previously described
(Del Vecchio et al., 1992; Schweiger et al., 2007). The PV LCRs in the
luciferase reporter vector pGL4.20 (Promega) have been described for
pGL4-LCRBPV1 (p5191, BPV1 nt 6958–91), pGL4-LCRHPV11 (p5192,
HPV11 nt 7072–102), and pGL4-LCRHPV18 (p5194, HPV18 nt 6943–
105) (Schweiger et al., 2007). The vector pGL4-LCRHPV16 (p5193)
was generated by introducing HPV16 genomic nucleotides 7000 to
100 (GenBank accession number NC_001526) into the SacI/BglII
sites of pGL4.20. An alternative pGL4-LCRHPV16 (p6239, HPV16 nt
7000–85) vector lacking the coding nucleotides 4–18 of the E6 gene
(genomic nt 86–100) was generated. The sequences of all LCR
elements in the reporter vectors were veriﬁed. The vector EGFPC1
(Clontech) was used in separate wells to determine transfection
efﬁciencies.
Transient transfections and luciferase based reporter assays
At 24 h prior to transfections, C33A, HeLa, SiHa, NOK hT, BJ hT, and
CV1 cells were seeded in 12-well plates at densities of 105, 4×104,
2×105, 2×105, 105, and 7×104, respectively, to result in subconﬂuent
monolayers. Cells were transfected with a total of 400 ng of DNA per
well composed of 25 ng LCR reporter plasmid, 25 ng of SV40-βGAL
reporter plasmid, and 350 ng of empty vector pCMV or E2 expression
constructs. For E2 titration experiments, the total amount of
transfected DNA was kept constant at 850 ng per well by utilizing
pCMV empty vector DNA. C33A, HeLa, SiHa, NOK hT, and BJ hT cells
were transfected using Fugene6 (Roche) with Fugene to DNA ratios
(μl/μg) of 2:1, 3:1, 4.5:1, 3.5:1, and 4:1, respectively. CV1 cells were
transfected with Effectene (Qiagen). At 48 h post-transfection, cells
were washed once in cold phosphate buffered saline, then lysed and
scraped on ice in reporter lysis buffer (Promega). Lysates were
subjected to one freeze–thaw cycle and spun at high speed for 1 min
to pellet the debris. Lysates were analyzed for luciferase activity using
a luciferase assay system (Promega) and for β-galactosidase (β-gal)
activity using a luminescent β-gal system (Clontech) on an Lmax1.1L
luminometer (Molecular Devices). The expression of some E2
proteins in certain cell types caused up to 2-fold increase in β-gal
activity. Therefore, the luciferase data presented in this work is not
normalized to β-gal. The results obtained with β-gal correction
(Supplementary Figs. S2 and S3) were qualitatively similar to results
without normalization to β-gal activity. All assays presented herein
represent at least three independent assays each performed in
duplicate.
Establishment of pools of stable cells and clonal selection of stable
cell lines
To generate C33A and CV1 cells with stably integrated LCR
reporters, pGL4.20, pGL4-LCRHPV11, pGL4-LCRHPV16, pGL4-
LCRHPV18, and pGL4-LCRBPV1 (see ‘DNA constructs’) were linearized
with NotI. Subconﬂuent C33A and CV1 cells were transfected with
10 μg of linearized DNA using Fugene6 or Effectene, respectively. At
1 day post-transfection, C33A and CV1 cells containing the LCRreporters were selected with puromycin at concentrations of
0.625 and 12.5 μg/ml, respectively. Pools of stable cells were kept
under selection and split as necessary to maintain subconﬂuence. In
addition, we generated C33A/E2TA cells with integrated pGL4-
LCRHPV18 by transfecting cells with 10 μg NotI-linearized pGL4-
LCRHPV18 and selecting with puromycin (0.75 μg/ml) for 10 days
before establishing multiple single-cell clones. Clonal cell lines were
maintained as subconﬂuent monolayers under puromycin selection.
Determination of DNA copy numbers of integrated HPV18 LCR reporters
using qPCR
DNA from 2×106 cells of C33A/E2TA/LCRHPV18 single-cell clones
and C33A/E2TA cells was extracted using a QIAamp DNA Blood Mini
kit (Qiagen). DNA (100 ng) was subjected to quantitative PCR (qPCR)
using a TaqMan protocol. Primers for HPV18 LCR were used at 900 nM
(18LCR taqmanFOR, 5′-GCATATAAGGCGCACCTGGTA-3′ [HPV18 nt
positions 7587–7607], 18LCR taqmanREV, 5′-GGGAGTGGATATAGT-
TATGCAAGCA-3′ [nt 7667–7643]). The 18 LCR probe was used at
250 nM (18LCR taqman probe, 5′-6-carboxyﬂuorescein [6-FAM]-
TAGTCATTTTCCTGTCCAGGTGCGCTACA-IowaBlackFQ-3′). TaqMan
Fast Universal PCR Master Mix 2x (Applied Biosystems) was used.
Cycling conditions were 95 °C for 20 s, followed by 45 cycles of 95 °C
for 3 s and 60 °C for 30 s on an ABI7500 Fast cycler (Applied
Biosystems). To obtain absolute copy numbers, a standard curve was
generated using a 10-fold serial dilution of pGL4-LCRHPV18 plasmid
DNA. Further, to adjust for differences in the relative amount of input
DNA, 50 ng of DNA was subjected to a glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) speciﬁc qPCR reaction using primers GAPDH
DNA FWD (5′-GGCATCCTGGGCTACACTGA-3′) and GAPDH DNA REV
(5′-GCCCCAGCGTCAAAGGT-3′) and the probe GAPDH DNA probe
(5′-6-FAM-CTCCTCTGACTTCAACAGCGACACCC-black hole quencher-
1-3′). Conditions for GAPDH and HPV18 LCR qPCR reactions were
identical. All reactions were performed in triplicate. Calculations of
HPV18 LCR copy numbers per cell were performed based on a DNA
content of 6.6 pg of DNA in a diploid cell.
siRNA knock-down of BPV1 E2
siRNA duplexes were purchased from Dharmacon. The target
sequences for BPV1 E2 #1 and #3 are ACAUGUAGCGCAAGAAACA and
CAACGGUGCUGAAAGACAA, respectively. C33A/E2TA/LCRHPV18 sin-
gle-cell clones were plated 1 day prior to transfection at 8×104 cells/
22-mm plate in hgDMEM + 10% heat-inactivated FBS. Cells were
transfected with siRNAs at a ﬁnal concentration of 10 nM using
Dharmafect2 according to the manufacturer's recommendations. As a
negative control, cells were transfected with 10 nM ON-TARGETplus
siRNA#1 (scr) (Dharmacon). After 24 h, medium was removed and
cells were incubated in hgDMEM + 10% FCS for an additional 24 h.
Forty-eight hours post-transfection, cells were harvested and relative
luciferase activity was determined as described above. In addition,
lysate protein concentrations were determined using a protein assay
kit (BCA protein assay kit, Thermo Scientiﬁc).
Immunoblotting
Cell lysates were normalized for protein content and sodium
dodecyl sulphate–polyacrylamide gel electrophoresis was performed.
Proteins were transferred to polyvinylidene ﬂuoride membranes and
immunodetection of HA-tagged BPV1 E2 with commercially available
anti-HA-peroxidase high afﬁnity monoclonal antibody (Roche) was
performed. For detection of actin, membranes were incubated with a
primary monoclonal anti-actin antibody (Millipore) and a secondary
AlexaFluor 680 conjugated goat anti-mouse IgG antibody (Molecular
Probes/Invitrogen). Labelled proteins were visualized using an
Odyssey Infrared Imaging System (LI-COR).
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